Protection of inactivated vaccine against SARS-CoV-2 infections in patients with comorbidities: a prospective cohort study

Abstract

Protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of inactivated vaccines is not well characterized in people with comorbidities, who are at high risk of severe infection. We compared the risk of SARS-CoV-2 infection after complete vaccination with Sinopharm/BBIBP in people with comorbidities (e.g., autoimmune diseases, cardiovascular disease, chronic lung disease, and diabetes) with healthy individuals using a Cox-proportional hazard model. In July–September 2021, a total of 10 548 people (comorbidities, 2143; healthy, 8405) receiving the complete primary series of vaccination with Sinopharm/BBIBP in Bangkok, Thailand were prospectively followed for SARS-CoV-2 infection through text messaging and telephone interviewing for 6 months. A total of 295 infections from 284 participants were found. HRs (95% CI) of individuals with any comorbidities did not increase (unadjusted, 1.02 (0.77–1.36), P = 0.89; adjusted, 1.04 (0.78–1.38), P = 0.81). HRs significantly increased in the subgroup of autoimmune diseases (unadjusted, 2.64 (1.09–6.38), P = 0.032; adjusted, 4.45 (1.83–10.83), P = 0.001) but not in cardiovascular disease, chronic lung disease, or diabetes. The protection against SARS-CoV-2 infection of the Sinopharm vaccine was similar in participants with any comorbidities vs. healthy individuals. However, the protection appeared lower in the subgroup of autoimmune diseases, which may reflect suboptimal immune responses among these people.

Keywords

COVID-19 / Sinopharm/BBIBP vaccine / immunocompromised patients / real-world

References

[1] World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020. WHO declared COVID-19 as a pandemic. 2020. Available at the website of WHO

[2] World Health Organization. COVID-19 vaccines with WHO emergency use listing. 2021. Available at the website of WHO

[3] Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021; 21(1): 39–51

[4] Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, Hussein SE, Al Mazrouei SK, Al Karam M, Li X, Yang X, Wang W, Lai B, Chen W, Huang S, Wang Q, Yang T, Liu Y, Ma R, Hussain ZM, Khan T, Saifuddin Fasihuddin M, You W, Xie Z, Zhao Y, Jiang Z, Zhao G, Zhang Y, Mahmoud S, ElTantawy I, Xiao P, Koshy A, Zaher WA, Wang H, Duan K, Pan A, Yang X. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA 2021; 326(1): 35–45

[5] Al Kaabi N, Oulhaj A, Ganesan S, Al Hosani FI, Najim O, Ibrahim H, Acuna J, Alsuwaidi AR, Kamour AM, Alzaabi A, Al Shehhi BA, Al Safar H, Hussein SE, Abdalla JS, Al Mansoori DSN, Al Hammadi AAK, Amari MA, Al Romaithi AK, Weber S, Elavalli S, Eltantawy I, Alghaithi NK, Al Azazi JN, Holt SG, Mostafa M, Halwani R, Khalak H, Elamin W, Beiram R, Zaher W. Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates. Nat Commun 2022; 13(1): 3215

[6] Zhang Y, Belayachi J, Yang Y, Fu Q, Rodewald L, Li H, Yan B, Wang Y, Shen Y, Yang Q, Mu W, Tang R, Su C, Xu T, Obtel M, Mhayi A, Razine R, Abouqal R, Zhang Y, Yang X. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. BMC Public Health 2022; 22(1): 1584

[7] PremikhaMChiew CJWeiWELeoYSOngB LyeDCLee VJTanKB. Comparative effectiveness of mRNA and inactivated whole-virus vaccines against coronavirus disease 2019 infection and severe disease in Singapore. Clin Infect Dis 2022 12; 75(8): 1442–1445 doi: 10.1093/cid/ciac288

[8] Lai FTT, Huang L, Chui CSL, Wan EYF, Li X, Wong CKH, Chan EWW, Ma T, Lum DH, Leung JCN, Luo H, Chan EWY, Wong ICK. Multimorbidity and adverse events of special interest associated with COVID-19 vaccines in Hong Kong. Nat Commun 2022; 13(1): 411

[9] Rydland HT, Friedman J, Stringhini S, Link BG, Eikemo TA. The radically unequal distribution of COVID-19 vaccinations: a predictable yet avoidable symptom of the fundamental causes of inequality. Humanit Soc Sci Commun 2022; 9(1): 61

[10] Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, Brenner SK, Leonberg-Yoo A, Schenck EJ, Radbel J, Reiser J, Bansal A, Srivastava A, Zhou Y, Sutherland A, Green A, Shehata AM, Goyal N, Vijayan A, Velez JCQ, Shaefi S, Parikh CR, Arunthamakun J, Athavale AM, Friedman AN, Short SAP, Kibbelaar ZA, Abu Omar S, Admon AJ, Donnelly JP, Gershengorn HB, Hernán MA, Semler MW, Leaf DE; STOP-COVID Investigators. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med 2020; 180(11): 1436–1447

[11] Holman N, Knighton P, Kar P, O’Keefe J, Curley M, Weaver A, Barron E, Bakhai C, Khunti K, Wareham NJ, Sattar N, Young B, Valabhji J. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol 2020; 8(10): 823–833

[12] Pablos JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, Gonzalez-Gay MA, Martinez-Lopez D, Castrejón I, Alvaro-Gracia JM, Fernández Fernández D, Mera-Varela A, Manrique-Arija S, Mena Vázquez N, Fernandez-Nebro A; RIER Investigators Group; RIER investigators group. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis 2020; 79(12): 1544–1549

[13] Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, Wang Y. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: a systematic review and meta-analysis. Int J Infect Dis 2020; 99: 47–56

[14] World Health Organization. WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines. 2022. Updated January 21, 2022 and August 16, 2022. Available at the website of WHO

[15] Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 2020; 159(2): 481–491.e3

[16] EkinACoskun BNDalkilicEPehlivanY. The effects of COVID-19 infection on the mortality of patients receiving rituximab therapy. Ir J Med Sci 2022; [Epub ahead of print]

[17] Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest 2020; 43(6): 867–869

[18] Ferri C, Giuggioli D, Raimondo V, L'Andolina M, Tavoni A, Cecchetti R, Guiducci S, Ursini F, Caminiti M, Varcasia G, Gigliotti P, Pellegrini R, Olivo D, Colaci M, Murdaca G, Brittelli R, Mariano GP, Spinella A, Bellando-Randone S, Aiello V, Bilia S, Giannini D, Ferrari T, Caminiti R, Brusi V, Meliconi R, Fallahi P, Antonelli A; COVID-19 & ASD Italian Study Group. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. Clin Rheumatol 2020; 39(11): 3195–3204

[19] Khan MMA, Khan MN, Mustagir MG, Rana J, Islam MS, Kabir MI. Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: a systematic review and meta-analysis. J Glob Health 2020; 10(2): 020503

[20] Pranata R, Huang I, Lim MA, Wahjoepramono EJ, July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression. J Stroke Cerebrovasc Dis 2020; 29(8): 104949

[21] Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: a systematic review and meta-analysis. PLoS One 2020; 15(8): e0238215

[22] Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY) 2020; 12(7): 6049–6057

[23] Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42(2): 377–381

[24] Srisubat A. Editorial. Journal of The Department of Medical Services. 2021; 46(2): 3

[25] Department of Medical Sciences, Ministry of Public Health. List of network laboratories that has been accredited for medical testing laboratories: Department of Medical Sciences. 2021. Available at the website of the Ministry of Public Health of Thailand

[26] Department of Medical Sciences, Ministry of Public Health. SARS-CoV-2 variants in Thailand. 2021. Updated August 1, 2022 and August 12, 2022. Available at the website of the Ministry of Public Health of Thailand

[27] Cardelli C, Caruso T, Tani C, Pratesi F, Talarico RDI, Cianni F, Italiano N, Laurino E, Moretti M, Cascarano G, Diomedi M, Gualtieri L, D’urzo R, Migliorini P, Mosca M. AB1152 COVID-19 mRNA vaccine booster in patients with systemic autoimmune diseases. Ann Rheum Dis 2022; 81(Suppl 1): 1693

[28] Pal R, Sachdeva N, Mukherjee S, Suri V, Zohmangaihi D, Ram S, Puri GD, Bhalla A, Soni SL, Pandey N, Bhansali A, Bhadada SK. Impaired anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with diabetes mellitus: a preliminary report. Diabetes Metab Syndr 2021; 15(1): 193–196

[29] Sourij C, Tripolt NJ, Aziz F, Aberer F, Forstner P, Obermayer AM, Kojzar H, Kleinhappl B, Pferschy PN, Mader JK, Cvirn G, Goswami N, Wachsmuth N, Eckstein ML, Müller A, Abbas F, Lenz J, Steinberger M, Knoll L, Krause R, Stradner M, Schlenke P, Sareban N, Prietl B, Kaser S, Moser O, Steinmetz I, Sourij H; COVAC-DM study group. Humoral immune response to COVID-19 vaccination in diabetes is age-dependent but independent of type of diabetes and glycaemic control: the prospective COVAC-DM cohort study. Diabetes Obes Metab 2022; 24(5): 849–858

[30] Marfella R, D’Onofrio N, Sardu C, Scisciola L, Maggi P, Coppola N, Romano C, Messina V, Turriziani F, Siniscalchi M, Maniscalco M, Boccalatte M, Napolitano G, Salemme L, Marfella LV, Basile E, Montemurro MV, Papa C, Frascaria F, Papa A, Russo F, Tirino V, Papaccio G, Galdiero M, Sasso FC, Barbieri M, Rizzo MR, Balestrieri ML, Angelillo IF, Napoli C, Paolisso G. Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: the CAVEAT study. Diabetes Obes Metab 2022; 24(1): 160–165

[31] World Health Organization. Noncommunicable diseases Thailand 2018 country profile. WHO Noncommunicable diseases country profiles 2018. 2018. Availableat the website of WHO

[32] Puavilai W, Laorugpongse D, Prompongsa S, Sutheerapatranont S, Siriwiwattnakul N, Muthapongthavorn N, Srilert P, Jakpechyothin J. Prevalence and some important risk factors of hypertension in Ban Paew District, second report. J Med Assoc Thai 2011; 94(9): 1069–1076

RIGHTS & PERMISSIONS

Higher Education Press